All In Biotech

Drug Trial Radar · NCT04342351

Early Treatment of ARNI on Myocardial Remodeling and Progress

Early Treatment of ARNI on Myocardial Remodeling and Progress in Patients With Post-AMI (EARLYmyo-CRPⅠ)

Last checked: Nov 20, 2026Latest source record: Apr 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

280

Planned (sponsor's estimate)

Start

May 1, 2020

Primary completion

May 1, 2021

Study completion Dec 30, 2021

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Myocardial remodeling following myocardial infarction (MI) is an important prognostic factor for heart function and adverse cardiovascular events, especially are intimately linked with heart failure. MI often causes deleterious changes in ventricular size, shape, and function. This adverse remodeling and progress is mediated by neurohormonal and hemodynamic alterations. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to an ACE inhibitor in patients with heart failure with reduced ejection fraction (HF-REF), reduce the risk of both death (from cardiovascular and all-causes) and heart failure hospitalization, may be a new approach to the treatment of heart failure. However, the impact of early treatment of ARNI on myocardial remodeling and progress, and aerobic exercise capacity in patients with prior MI has yet to be assessed. The aim of this study is to evaluate the efficacy and the safety of early treatment of ARNI on myocardial remodeling and progress, and aerobic exercise capacity in patients following MI.

Conditions

  • Myocardial Infarction

Interventions

  • sacubitril/valsartanDrug

    sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs

  • perindoprilDrug

    Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur

  • Cardiopulmonary Exercise TestOther

    All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.

  • EchocardiogramOther

    An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak oxygen consumption (VO2)/kgTime frame: 3 months
  2. Peak Oxygen Pulse (O2-Pulse)Time frame: 3 months
  3. LVEFTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RenJi Hospital, Shanghai JiaoTong University, School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.